Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Authors
Keywords
-
Journal
JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-26
DOI
10.1007/s00415-022-11296-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
- (2022) Marton König et al. JAMA Neurology
- Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
- (2022) Anat Achiron et al. JOURNAL OF NEUROLOGY
- Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab
- (2022) Natacha Madelon et al. JAMA Neurology
- Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
- (2022) Rocco Capuano et al. Multiple Sclerosis and Related Disorders
- Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
- (2022) Alessandro Maglione et al. Multiple Sclerosis and Related Disorders
- Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies
- (2021) Fabrizio Bonelli et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- WHO International Standard for anti-SARS-CoV-2 immunoglobulin
- (2021) Paul A Kristiansen et al. LANCET
- mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis
- (2021) Massimiliano Di Filippo et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
- (2021) Sokratis A. Apostolidis et al. NATURE MEDICINE
- Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
- (2021) Antonio Gallo et al. NEUROLOGICAL SCIENCES
- Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
- (2021) Livnat Brill et al. JAMA Neurology
- Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
- (2021) Maria Pia Sormani et al. EBioMedicine
- COVID ‐19 Vaccine Response in People with Multiple Sclerosis
- (2021) Emma C. Tallantyre et al. ANNALS OF NEUROLOGY
- Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients
- (2020) M. C. Kowarik et al. Neurotherapeutics
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More